CRISPR Therapeutics CRSP Operating margin
Operating margin at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's operating margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's operating margin?
- CRISPR Therapeutics (CRSP) reported operating margin of -15,754.2% in Q1 2026.
- How has CRISPR Therapeutics's operating margin changed year-over-year?
- CRISPR Therapeutics's operating margin decreased by 1151.1% year-over-year, from -1,259.2% to -15,754.2%.
- What is the long-term trend for CRISPR Therapeutics's operating margin?
- Over 3 years (2020 to 2025), CRISPR Therapeutics's operating margin has grown at a -27.3% compound annual growth rate (CAGR), from -49,295.5% to -18,933.6%.
- What does operating margin mean?
- Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.